76 studies found for:    INCB018424 | Exclude Unknown
Show Display Options
Rank Status Study
21 Active, not recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
22 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
23 Recruiting Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Ruxolitinib;   Drug: Placebo;   Drug: Pemetrexed;   Drug: Cisplatin
24 Recruiting Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Condition: Lung Cancer
Interventions: Drug: Ruxolitinib;   Drug: Erlotinib
25 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
26 Recruiting Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Neutrophilic Leukemia
Interventions: Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
27 Active, not recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
28 Recruiting Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   PMF;   SMF;   Post-PV MF;   Post-ET MF
Intervention: Drug: INCB018424/CC-4047
29 Recruiting Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Conditions: Idiopathic Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis;   Post Polycythemia-Vera Myelofibrosis
Interventions: Drug: panobinostat;   Drug: ruxolitinib
30 Completed A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 Phosphate Cream;   Drug: Placebo Cream
31 Not yet recruiting Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
32 Active, not recruiting Ruxolitinib in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
33 Recruiting Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Drug: Momelotinib;   Drug: Ruxolitinib;   Drug: Placebo to match momelotinib;   Drug: Placebo to match ruxolitinib
34 Active, not recruiting Study of Ruxolitinib in Pancreatic Cancer Patients
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Capecitabine;   Drug: Ruxolitinib;   Drug: Placebo
35 Recruiting Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Conditions: Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel
36 Not yet recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
37 Recruiting Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Condition: Myeloproliferative Neoplasms
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
38 Recruiting A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Condition: Advanced or Metastatic HER2-negative Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Capecitabine;   Drug: Placebo
39 Recruiting Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Condition: Leukemia
Interventions: Drug: Ruxolitinib (RUX);   Drug: Azacitidine (AZA);   Behavioral: Questionnaires
40 Active, not recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib;   Drug: hydroxyurea (HU);   Drug: placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years